Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib

INTRODUCTION: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard of care for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). However, questions remain about the optimal treatment sequence of EGFR TKIs. The global, observational GioTag...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Nobuyuki, Mera, Takeshi, Märten, Angela, Hochmair, Maximilian J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004431/
https://www.ncbi.nlm.nih.gov/pubmed/31863283
http://dx.doi.org/10.1007/s12325-019-01187-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004431/
https://www.ncbi.nlm.nih.gov/pubmed/31863283
http://dx.doi.org/10.1007/s12325-019-01187-y

Ejemplares similares